Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Sept 2015

Ercan Dalia, Choi Hwan Geun, Yun Cai-Hong, Capelletti Marzia, Xie Ting, Eck Michael J, Gray Nathanael S, Jänne Pasi A

Abstract excerpt

PURPOSE: Mutant selective irreversible pyrimidine-based EGFR kinase inhibitors, including WZ4002, CO-1686, and AZD9291, are effective in preclinical models and in lung cancer patients harboring the EGFR T790M gefitinib/erlotinib resistance mutation. However, little is known about how cancers develop acquired resistance to this class of EGFR inhibitors. We sought to identify and study EGFR mutations that confer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Inhibitory Concentration 50

Share to Molecular Conformation

Share to Pyrimidines

Share to Quinazolines

Source

Open in PubMed Open full text

Identifiers

PMID: 25948633
DOI: 10.1158/1078-0432.CCR-14-2789
PMCID: PMC4791951

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors.PMID 25948633Read ↗

Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M.Semantic proximity Read ↗

Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.Semantic proximity Read ↗

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.Semantic proximity Read ↗

In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing.Semantic proximity Read ↗

Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.Semantic proximity Read ↗

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.Semantic proximity Read ↗

Targeting EGFRL858R/T790M and EGFRL858R/T790M/C797S resistance mutations in NSCLC: Current developments in medicinal chemistry.Semantic proximity Read ↗

Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutationSemantic proximity Read ↗

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.Semantic proximity Read ↗

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.Semantic proximity Read ↗

EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved and In-Development Lung Cancer EGFR Tyrosine Kinase InhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.